Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite ß­decitabine in human plasma, whole blood and urine.

Roosendaal, Jeroen; Wang, Kai; Rosing, Hilde; Lucas, Luc; Gebretensae, Abadi; Oganesian, Aram; Schellens, Jan H M; Beijnen, Jos H; Lin, Zhongping John

Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite ßdecitabine in human plasma, whole blood and urine.

Roosendaal, Jeroen; Wang, Kai; Rosing, Hilde; Lucas, Luc; Gebretensae, Abadi; Oganesian, Aram; Schellens, Jan H M; Beijnen, Jos H; Lin, Zhongping John.

Afiliação

Roosendaal J; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek and MC Slotervaart, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Science Faculty, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, th
Wang K; Frontage Laboratories, Inc., Exton, PA, United States of America.
Rosing H; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek and MC Slotervaart, Amsterdam, the Netherlands.
Lucas L; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek and MC Slotervaart, Amsterdam, the Netherlands.
Gebretensae A; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek and MC Slotervaart, Amsterdam, the Netherlands.
Oganesian A; Astex Pharmaceuticals, Inc., Pleasanton, CA, United States of America.
Schellens JHM; Division of Pharmacoepidemiology and Clinical Pharmacology, Science Faculty, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Division of Clinical Pharmacology, Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterda
Beijnen JH; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek and MC Slotervaart, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Science Faculty, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, th
Lin ZJ; Frontage Laboratories, Inc., Exton, PA, United States of America.

J Chromatogr B Analyt Technol Biomed Life Sci ; 1109: 132-141, 2019 Mar 01.

Article em En | MEDLINE | ID: mdl-30754019

Assuntos

Antineoplásicos/sangue; Azacitidina/análogos & derivados; Cromatografia Líquida/métodos; Decitabina/sangue; Espectrometria de Massas em Tandem/métodos; Antineoplásicos/química; Antineoplásicos/farmacocinética; Antineoplásicos/urina; Azacitidina/sangue; Azacitidina/química; Azacitidina/farmacocinética; Azacitidina/urina; Decitabina/química; Decitabina/farmacocinética; Decitabina/urina; Humanos; Modelos Lineares; Reprodutibilidade dos Testes; Sensibilidade e Especificidade

Palavras-chave

Bioanalysis; Decitabine; Guadecitabine; LC-MS/MS; Pharmacokinetics; SGI-110

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azacitidina / Cromatografia Líquida / Espectrometria de Massas em Tandem / Decitabina / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Chromatogr B Analyt Technol Biomed Life Sci Assunto da revista: ENGENHARIA BIOMEDICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Tailândia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google